 <h1>Naglazyme Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>galsulfase</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about galsulfase. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Naglazyme.</p><h2>In Summary</h2><p><b>Common side effects of Naglazyme include:</b> severe infusion related reaction, conjunctivitis, rigors, chest pain, development of igg antibodies, dyspnea, infusion related reaction, otalgia, pain, and pharyngitis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to galsulfase: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, galsulfase (the active ingredient contained in Naglazyme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking galsulfase:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred or decreased vision</li>
<li>chest pain</li>
<li>difficult or labored breathing</li>
<li>dizziness</li>
<li>headache</li>
<li>hernia of the naval</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>swelling of the face</li>
<li>tightness in the chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back pain</li>
<li>bluish lips or skin</li>
<li>confusion</li>
<li>cough</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fever, chills, or sweating</li>
<li>hives or welts</li>
<li>joint pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of bladder control</li>
<li>loss of bowel control</li>
<li>nausea or vomiting</li>
<li>paralysis of the limbs</li>
<li>stomach pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of galsulfase may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>ear pain</li>
<li>loss of appetite</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>burning, dry, or itching eyes</li>
<li>congestion</li>
<li>dryness or soreness of the throat</li>
<li>excessive tearing</li>
<li>loss of or increase in reflexes</li>
<li>runny or stuffy nose</li>
<li>tender, swollen glands in the neck</li>
<li>trouble with swallowing</li>
<li>unusual tiredness or weakness</li>
<li>voice changes</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Difficulty with moving</li>
<li>loss of voice</li>
<li>muscle pain or stiffness</li>
<li>sneezing</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to galsulfase: intravenous solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions included rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain, and dyspnea.</p>
<p></p>
<p>The most frequently reported adverse reactions requiring interventions are infusion-related reactions.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis/anaphylactoid reaction, allergic reaction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (21%), angioedema, urticaria, pruritus</p>
<p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (47%), gastroenteritis (11%), umbilical hernia (11%), nausea, vomiting<sup>[Ref]</sup></p><h3>Other</h3><p>Infusion reactions, which occurred in 56% of patients across 5 clinical studies were defined as adverse reactions occurring during infusions or until the end of the infusion day.  Infusion reactions were observed as early as week 1 and as late as week 146 of treatment and occurred during multiple infusions, however, not always in consecutive weeks.  The most common signs/symptoms included pruritus, vomiting, abdominal pain, nausea, hypertension, headache, chest pain, erythema, cough, hypotension, angioedema, respiratory distress, tremor, conjunctivitis, malaise, bronchospasm, and arthralgia.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Infusion reactions (56%), ear pain (42%), pain (32%), chills/rigors (21%), chest pain (16%), malaise (11%), hearing impairment (11%), pyrexia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (11%)</p>
<p><b>Common</b> (1% to 10%): Hypotension</p>
<p><b>Frequency not reported</b>: Pallor, bradycardia, tachycardia, cyanosis, shock<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Areflexia (11%), headache</p>
<p><b>Common</b> (1% to 10%): Tremor</p>
<p><b>Frequency not reported</b>: Paresthesia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%), pharyngitis (11%), nasal congestion (11%)</p>
<p><b>Common</b> (1% to 10%): Apnea, cough, respiratory distress, asthma, bronchospasm</p>
<p><b>Frequency not reported</b>: Laryngeal edema, hypoxia, tachypnea, sleep apnea</p>
<p><b>Postmarketing reports</b>: Respiratory failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (42%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (21%), corneal opacity (11%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p>During clinical trials, 53 out of 54 patients tested positive for antidrug IgG antibodies within 4 to 8 weeks of treatment.  In the placebo controlled study, 19 patients were evaluated for a potential relationship between development of antidrug antibodies to clinical outcome measures.  While all 19 patients developed antidrug antibodies, there was no consistent predictive relationship between total antibody titer, neutralizing or IgE antibodies, and infusion-associated reactions, urinary glycosaminoglycan (GAG) levels, or endurance measures.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Development of antidrug antibodies (98%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Membranous nephropathy<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_3">3. "Product Information. Naglazyme (galsulfase)." BioMarin Pharmaceutical Inc, Novato, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Naglazyme (galsulfase)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Naglazyme &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mucopolysaccharidosis Type VI</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to galsulfase: intravenous solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions included rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain, and dyspnea.</p><p></p><p>The most frequently reported adverse reactions requiring interventions are infusion-related reactions.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis/anaphylactoid reaction, allergic reaction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (21%), angioedema, urticaria, pruritus</p><p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (47%), gastroenteritis (11%), umbilical hernia (11%), nausea, vomiting<sup>[Ref]</sup></p><h3>Other</h3><p>Infusion reactions, which occurred in 56% of patients across 5 clinical studies were defined as adverse reactions occurring during infusions or until the end of the infusion day.  Infusion reactions were observed as early as week 1 and as late as week 146 of treatment and occurred during multiple infusions, however, not always in consecutive weeks.  The most common signs/symptoms included pruritus, vomiting, abdominal pain, nausea, hypertension, headache, chest pain, erythema, cough, hypotension, angioedema, respiratory distress, tremor, conjunctivitis, malaise, bronchospasm, and arthralgia.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Infusion reactions (56%), ear pain (42%), pain (32%), chills/rigors (21%), chest pain (16%), malaise (11%), hearing impairment (11%), pyrexia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (11%)</p><p><b>Common</b> (1% to 10%): Hypotension</p><p><b>Frequency not reported</b>: Pallor, bradycardia, tachycardia, cyanosis, shock<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Areflexia (11%), headache</p><p><b>Common</b> (1% to 10%): Tremor</p><p><b>Frequency not reported</b>: Paresthesia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%), pharyngitis (11%), nasal congestion (11%)</p><p><b>Common</b> (1% to 10%): Apnea, cough, respiratory distress, asthma, bronchospasm</p><p><b>Frequency not reported</b>: Laryngeal edema, hypoxia, tachypnea, sleep apnea</p><p><b>Postmarketing reports</b>: Respiratory failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (42%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (21%), corneal opacity (11%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p>During clinical trials, 53 out of 54 patients tested positive for antidrug IgG antibodies within 4 to 8 weeks of treatment.  In the placebo controlled study, 19 patients were evaluated for a potential relationship between development of antidrug antibodies to clinical outcome measures.  While all 19 patients developed antidrug antibodies, there was no consistent predictive relationship between total antibody titer, neutralizing or IgE antibodies, and infusion-associated reactions, urinary glycosaminoglycan (GAG) levels, or endurance measures.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Development of antidrug antibodies (98%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Membranous nephropathy<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_3">3. "Product Information. Naglazyme (galsulfase)." BioMarin Pharmaceutical Inc, Novato, CA. </p><h2>More about Naglazyme (galsulfase)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Naglazyme &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mucopolysaccharidosis Type VI</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>